Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
(2015) In Leukemia & Lymphoma 56(4). p.866-876- Abstract
- Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular... (More)
- Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular pathogenesis of the disease and how these underlying molecular alterations may guide the selection and integration of innovative approaches for therapy. This review of the meeting covers in particular the identification of indolent cases, and deals with the role of the B-cell receptor pathway in MCL, as well as the detection of minimal residual disease and implementation of molecular approaches in current clinical trials. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7439153
- author
- Dreyling, Martin ; Amador, Virginia ; Callanan, Mary ; Jerkeman, Mats LU ; Le Goui, Steven ; Pott, Christiane ; Rule, Simon and Zaja, Francesco
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Mantle cell lymphoma, chemotherapy, targeted therapy, molecular, pathogenesis, minimal residual disease
- in
- Leukemia & Lymphoma
- volume
- 56
- issue
- 4
- pages
- 866 - 876
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000353612700009
- scopus:84929085168
- pmid:25015778
- ISSN
- 1042-8194
- DOI
- 10.3109/10428194.2014.940584
- language
- English
- LU publication?
- yes
- id
- d067018c-11f3-43d6-89e7-4eac4a7b5079 (old id 7439153)
- date added to LUP
- 2016-04-01 13:20:12
- date last changed
- 2022-01-27 18:35:33
@article{d067018c-11f3-43d6-89e7-4eac4a7b5079,
abstract = {{Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular pathogenesis of the disease and how these underlying molecular alterations may guide the selection and integration of innovative approaches for therapy. This review of the meeting covers in particular the identification of indolent cases, and deals with the role of the B-cell receptor pathway in MCL, as well as the detection of minimal residual disease and implementation of molecular approaches in current clinical trials.}},
author = {{Dreyling, Martin and Amador, Virginia and Callanan, Mary and Jerkeman, Mats and Le Goui, Steven and Pott, Christiane and Rule, Simon and Zaja, Francesco}},
issn = {{1042-8194}},
keywords = {{Mantle cell lymphoma; chemotherapy; targeted therapy; molecular; pathogenesis; minimal residual disease}},
language = {{eng}},
number = {{4}},
pages = {{866--876}},
publisher = {{Taylor & Francis}},
series = {{Leukemia & Lymphoma}},
title = {{Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network}},
url = {{https://lup.lub.lu.se/search/files/3310972/8523592.pdf}},
doi = {{10.3109/10428194.2014.940584}},
volume = {{56}},
year = {{2015}},
}